Skip to main content
. 2015 Mar 30;112(15):4737–4742. doi: 10.1073/pnas.1403685112

Fig. 1.

Fig. 1.

BHPI selectively inhibits proliferation of ERα+ cancer cells sensitive or resistant to drug therapy. BHPI inhibits proliferation of ERα+ (A) MCF-7 breast, (B) PEO4 ovarian, and (C) ECC-1 endometrial cancer cells with no effects on (D) counterpart ERα− cancer cells. Effects of BHPI on proliferation of drug-resistant cells: tamoxifen- and ICI-resistant (E) ZR-75-1 cells and (F) BT-474 breast cancer cells. (G) T47D cells treated with 1 μM BHPI or competitor antiestrogens (4-OHT, RAL, ICI) in the presence or absence of E2 and/or EGF. Proliferation of (H) cisplatin-resistant Caov-3 ovarian cancer cells and (I) multidrug-resistant OVCAR-3 ovarian cancer cells treated with BHPI, or the antiestrogens 4-OHT or ICI. Concentrations are as follows: E2, 1 nM (E, G, and H) or 10 nM (A–C, F, and I); EGF, 50 ng/mL (G); ICI, 1 μM (E, G, and H), 5 μM (I); 4-OHT, 1 μM (E, G, and H); RAL, 1 μM (G) “•” denotes cell number at day 0. Hatched bars denote antiestrogens (4-OHT, RAL, or ICI). Cell proliferation is expressed as mean ± SEM (n = 6).